Legal
Insys continues to receive an optics beating in the wake of the charges against company founder John Kapoor and multiple executives surrounding illegal sales practices of its cancer pain drug.
Last week a federal judge asked prosecutors and the FBI to look into possible witness tampering.
Once again Insys has been rocked by an indictment.
Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
The case was part of a consolidated trial of four women who were awarded a total of $26.7 million in compensatory damages.
The way the university handled it violated state law, according to state officials.
The company was among dozens of firms worldwide hit in the June 27 attack.
Mark Lanier, a lead attorney for the plaintiffs in one of six cases being tried raised the tampering issue during an Oct. 16 hearing.
The lawsuit was filed on behalf of members of the American military who were injured or killed by attacks between 2005 and 2009
PRESS RELEASES